» Articles » PMID: 22322863

MiR-182 Overexpression in Tumourigenesis of High-grade Serous Ovarian Carcinoma

Overview
Journal J Pathol
Specialty Pathology
Date 2012 Feb 11
PMID 22322863
Citations 91
Authors
Affiliations
Soon will be listed here.
Abstract

Molecular pathogenesis of high-grade serous ovarian carcinoma (HG-SOC) is poorly understood. Recent recognition of HG-SOC precursor lesions, defined as serous tubal intraepithelial carcinoma (STIC) in fimbria, provides a new venue for the study of early genetic changes in HG-SOC. Using microRNA profiling analysis, we found that miR-182 expression was significantly higher in STIC than in matched normal Fallopian tube. Further study revealed that miR-182 was significantly overexpressed in most HG-SOC cases. To test whether miR-182 plays a major role in early tumourigenesis of HG-SOC, we overexpressed miR-182 in immortalized ovarian surface, Fallopian tube secretory cells and malignant ovarian cell lines, and found that miR-182 overexpression resulted in increased tumour transformation in vitro, and enhanced tumour invasiveness in vitro and metastasis in vivo. Mechanistically, we demonstrated that the oncogenic properties of miR-182 in ovarian cancer were mediated in part by its impaired repair of DNA double-strand breaks and negative regulation of breast cancer 1 (BRCA1) and metastasis suppressor 1 (MTSS1) expression as well as its positive regulation of the oncogene high-mobility group AT-hook 2 (HMGA2). Our findings suggest that miR-182 dysregulation confers powerful oncogenic potential in the tumourigenesis of HG-SOC. Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Citing Articles

Emerging biologic and clinical implications of miR-182-5p in gynecologic cancers.

Zehtabi M, Ghaedrahmati F, Gale Dari M, Moramezi F, Kempisty B, Mozdziak P Clin Transl Oncol. 2024; .

PMID: 39661239 DOI: 10.1007/s12094-024-03822-9.


Bioinformatics and Experimental Insights Into miR-182, hsa_circ_0070269, and circ-102,166 as Therapeutic Targets for HCV-Associated HCC.

Ishaq Y, Rauff B, Alzahrani B, Ikram A, Javed H, Abdullah I Cancer Rep (Hoboken). 2024; 7(12):e70049.

PMID: 39617640 PMC: 11608829. DOI: 10.1002/cnr2.70049.


MicroRNA Expression Profiles in Human Samples and Cell Lines Revealed Nine miRNAs Associated with Cisplatin Resistance in High-Grade Serous Ovarian Cancer.

Flores-Colon M, Rivera-Serrano M, Reyes-Burgos V, Rolon J, Perez-Santiago J, Marcos-Martinez M Int J Mol Sci. 2024; 25(7).

PMID: 38612604 PMC: 11011404. DOI: 10.3390/ijms25073793.


Splicing Factor PQBP1 Curtails BAX Expression to Promote Ovarian Cancer Progression.

Liu X, Zhang J, Wang Z, Yan M, Xu M, Li G Adv Sci (Weinh). 2024; 11(15):e2306229.

PMID: 38342602 PMC: 11022708. DOI: 10.1002/advs.202306229.


Mutant p53 Gain-of-Function Induces Migration and Invasion through Overexpression of miR-182-5p in Cancer Cells.

Madrigal T, Ortega-Bernal D, Herrera L, Gonzalez-De la Rosa C, Dominguez-Gomez G, Arechaga-Ocampo E Cells. 2023; 12(20).

PMID: 37887350 PMC: 10605582. DOI: 10.3390/cells12202506.